The Regents of the University of California

United States of America

Back to Profile

Receive daily alerts for new
USPTO trademarks filed by this owner
1-100 of 1,203 for The Regents of the University of California Sort by
Query
Patent
Canada - CIPO
Aggregations Reset Report
Date
2020 September 1
2020 1
2019 107
2018 103
2017 93
See more
IPC Class
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids 128
A61P 35/00 - Antineoplastic agents 84
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum 77
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells 68
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy 65
See more
Status
Pending 586
Registered / In Force 617
Found results for  patents
  1     2     3     ...     13        Next Page

1.

SYSTEMS, METHODS, AND MEDIA FOR AUTOMATICALLY SEGMENTING AND DIAGNOSING PROSTATE LESIONS USING MULTI-PARAMETRIC MAGNETIC RESONANCE IMAGING DATA

      
Document Number 03074064
Status Pending
Filing Date 2020-02-27
Open to Public Date 2020-09-01
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Sung, Kyung Hyun
  • Cao, Ruiming

Abstract

In accordance with some embodiments, systems, methods, and media for automatically segmenting and diagnosing prostate lesions using multi-parametric magnetic resonance imaging (mp-MRI) data are provided. In some embodiments, the system comprises is programmed to: receive mp-MRI data depicting a prostate, including T2w data and ADC data; provide the T2w data and ADC data as input to first and second input channels of a trained convolutional neural network (CNN); receive, from the trained CNN, output values from output channels indicating which pixels are likely to correspond to a particular class of prostate lesion, the channels corresponding to predicted aggressiveness in order of increasing aggressiveness, identify a prostate lesion in the data based on output values greater than a threshold; predict an aggressiveness based on which channel had values over the threshold; and present an indication that a prostate lesion of the predicted aggressiveness is likely present in the prostate.

IPC Classes  ?

  • G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
  • G06K 9/62 - Methods or arrangements for recognition using electronic means
  • G06N 3/02 - Computer systems based on biological models using neural network models
  • A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging

2.

STEM CELL-ENGINEERED INKT CELL-BASED OFF-THE-SHELF CELLULAR THERAPY

      
Document Number 03102801
Status Pending
Filing Date 2019-06-12
Open to Public Date 2019-12-19
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Yang, Lili
  • Zhu, Yanni
  • Seet, Christopher
  • Montel-Hagen, Amelie
  • Crooks, Gay, Miriam

Abstract

Embodiments of the disclosure include compositions and methods related to engineered invariant natural killer T (iNKT) cells for off-the-shelf use for clinical therapy. In particular embodiments, the iNKT cells are produced from hematopoietic stem progenitorcells and also are suitable for allogeneic cellular therapy because they are HLA negative. In specific embodiments, the cells are cultured in a particular in vitro three-dimensional artificial thymic organoid system and the cells have imaging and suicide targeting capabilities.

IPC Classes  ?

  • A61K 35/14 - Blood; Artificial blood
  • C12N 5/074 - Adult stem cells
  • C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • C12N 9/22 - Ribonucleases
  • C12N 15/09 - Recombinant DNA-technology
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof
  • C12N 15/12 - Genes encoding animal proteins
  • C12N 15/33 - Genes encoding viral proteins
  • C12N 15/52 - Genes encoding for enzymes or proenzymes
  • C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

3.

SYNTHETIC CYTOTOXIC MOLECULES, DRUGS, METHODS OF THEIR SYNTHESIS AND METHODS OF TREATMENT

      
Document Number 03103805
Status Pending
Filing Date 2019-06-14
Open to Public Date 2019-12-19
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • THE UNIVERSITE DE MONTREAL (Canada)
Inventor
  • Edinger, Aimee
  • Hanessian, Stephen

Abstract

Small molecules compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, neoplasms, cancers, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.

IPC Classes  ?

  • C07D 207/12 - Oxygen or sulfur atoms
  • A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
  • A61P 35/00 - Antineoplastic agents
  • C07D 207/06 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
  • C07D 207/08 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
  • C07D 487/04 - Ortho-condensed systems

4.

DEMETHYLATION TO TREAT EYE DISEASE

      
Document Number 03103436
Status Pending
Filing Date 2019-05-29
Open to Public Date 2019-12-19
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Skowronska-Krawczyk, Dorota
  • Chao, Daniel Lee
  • Chen, Daniel

Abstract

Methods for treating age-related eye diseases or conditions are provided. Methods for treating an age-related eye disease or condition in a subject by administering one or more demethylation compounds or agents are provided.

IPC Classes  ?

  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • C12N 9/10 - Transferases (2.)
  • C12P 7/64 - Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats

5.

SINGLE-CHAIN BISPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER

      
Document Number 03103610
Status Pending
Filing Date 2019-06-12
Open to Public Date 2019-12-19
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Chen, Yvonne Yu-Hsuan
  • Zah, Eugenia

Abstract

Methods and compositions are provided concerning a bispecific chimeric antigen receptor (CAR) targeting BCMA and CS1, particularly in multiple myeloma patients. The bispecific CAR has advantages over dual or separate BCMA and CS1 CAR molecules. In some embodiments, there is a bispecific chimeric antigen receptor comprising a) a bispecific extracellular binding domain comprising both i) a BCMA-binding region and ii) a CS1- binding region; b) a single transmembrane domain; and, c) a single cytoplasmic region comprising a primary intracellular signaling domain.

IPC Classes  ?

  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
  • C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • C07K 16/46 - Hybrid immunoglobulins

6.

NEURAL STEM CELL COMPOSITIONS AND METHODS TO TREAT NEURODEGENERATIVE DISORDERS

      
Document Number 03102362
Status Pending
Filing Date 2018-06-06
Open to Public Date 2019-12-12
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Reidling, John
  • Fury, Brian
  • Thompson, Leslie Michels
  • Bauer, Gerhard
  • Coleal-Bergum, Dane

Abstract

Provided herein are stem-cell based therapies for the treatment of neurodegenerative diseases and CNS disorder such as Huntington's disease. The therapy improved motor deficits and rescued synaptic alterations. The cells were shown to be electrophysiologically active and that they improved motor and late-stage cognitive impairment.

IPC Classes  ?

  • C12N 5/0797 - Stem cells; Progenitor cells
  • C12N 5/0735 - Embryonic stem cells; Embryonic germ cells
  • C12N 5/079 - Neural cells
  • A01K 67/027 - New breeds of vertebrates
  • A61K 35/30 - Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

7.

TISSUE INTEGRATED DRUG DELIVERY SYSTEM

      
Document Number 03102776
Status Pending
Filing Date 2019-01-16
Open to Public Date 2019-12-12
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Thorson, Todd J.
  • Groisman, Luciano
  • Mohraz, Ali
  • Botvinick, Elliot L.

Abstract

Infusion sets for subcutaneous drug delivery are described herein. The infusion set integrates a bijel-templated material (BTM) into a cannula such that a portion of the BTM protrudes from the cannula tip into the host tissue. The BTM is a porous, polymeric sponge having a co-continuous architecture with consistent curvature throughout non-constricting, interpenetrating channels, which is critical in mitigation of the deleterious host tissue response, vascularization, and flow redistribution in the implant.

IPC Classes  ?

  • A61M 5/32 - Syringes - Details - Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
  • A61L 26/00 - Chemical aspects of, or use of materials for, liquid bandages
  • A61L 31/14 - Materials characterised by their function or physical properties
  • A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic

8.

MULTISTRAIN POPULATION CONTROL SYSTEMS AND METHODS

      
Document Number 03102955
Status Pending
Filing Date 2019-06-07
Open to Public Date 2019-12-12
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Hasty, Jeff
  • Liao, Michael Julius
  • Din, Muhammad Omar

Abstract

Provided herein are multi-strain population control systems, methods, kits, and compositions. Also provided are methods, systems, kits, and compositions for culturing bacterial cells in multi-strain ecosystems, and temporally arranged multi-strain ecosystems or cultures using a synchronized lysis circuit in combination with multiple toxin/antitoxin systems to cycle continuously over a long period of time.

IPC Classes  ?

  • A61K 35/74 - Bacteria
  • A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P 31/04 - Antibacterial agents
  • A61P 35/00 - Antineoplastic agents
  • C12N 1/20 - Bacteria; Culture media therefor
  • C12P 39/00 - Processes involving microorganisms of different genera in the same process, simultaneously

9.

METHODS OF PRODUCING NUCLEIC ACID LIBRARIES AND COMPOSITIONS AND KITS FOR PRACTICING SAME

      
Document Number 03100983
Status Pending
Filing Date 2019-06-05
Open to Public Date 2019-12-12
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Green, Richard
  • Kapp, Joshua

Abstract

Provided are methods of producing nucleic acid libraries. The methods include combining single-stranded nucleic acid binding protein-bound single-stranded nucleic acid (SSB-bound ssNA), an adapter oligonucleotide, and a splint oligonucleotide, to form complexes including the splint oligonucleotide hybridized to a terminal region of the SSB-bound ssNA and to the adapter oligonucleotide. An end of the first adapter oligonucleotide is adjacent to an end of the first terminal region of the SSB-bound ssNA, and the methods may further include covalently linking the adjacent ends. Also provided are compositions and kits that find use, e.g., in practicing the methods of the present disclosure.

IPC Classes  ?

  • C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

10.

DEEP LEARNING-ENABLED PORTABLE IMAGING FLOW CYTOMETER FOR LABEL-FREE ANALYSIS OF WATER SAMPLES

      
Document Number 03102297
Status Pending
Filing Date 2019-06-04
Open to Public Date 2019-12-12
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Ozcan, Aydogan
  • Gorocs, Zoltan

Abstract

An imaging flow cytometer device includes a housing holding a multi-color illumination source configured for pulsed or continuous wave operation. A microfluidic channel is disposed in the housing and is fluidically coupled to a source of fluid containing objects that flow through the microfluidic channel. A color image sensor is disposed adjacent to the microfluidic channel and receives light from the illumination source that passes through the microfluidic channel. The image sensor captures image frames containing raw hologram images of the moving objects passing through the microfluidic channel. The image frames are subject to image processing to reconstruct phase and/or intensity images of the moving objects for each color. The reconstructed phase and/or intensity images are then input to a trained deep neural network that outputs a phase recovered image of the moving objects. The trained deep neural network may also be trained to classify object types.

IPC Classes  ?

  • G01N 15/10 - Investigating individual particles
  • C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters

11.

MICROFLUIDIC FILTER DEVICE AND METHOD FOR DISSOCIATION OF TISSUE AND CELL AGGREGATES AND ENRICHMENT OF SINGLE CELLS

      
Document Number 03101987
Status Pending
Filing Date 2019-05-29
Open to Public Date 2019-12-05
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Haun, Jered
  • Qiu, Xiaolong
  • Pennell, Marissa Noelani
  • Hui, Elliot E.

Abstract

A microfluidic tissue dissociation and filtration device simultaneously filters large tissue fragments and dissociates smaller aggregates into single cells, thereby improving single cell yield and purity. The device includes an inlet coupled to a first microfluidic channel at an upstream location and a first outlet at a downstream location. A first filter membrane is interposed between the first microfluidic channel and a second microfluidic channel, wherein the second microfluidic channel is in fluidic communication with the first microfluidic channel via the first filter membrane. The first filter membrane operates under a tangential flow format. A second outlet is coupled to a downstream location of the second microfluidic channel and includes a second filter membrane interposed between the second outlet and the second microfluidic channel. The dual membrane device increased single cell numbers by at least 3-fold for different tissue types.

IPC Classes  ?

  • C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
  • B01D 11/04 - Solvent extraction of solutions which are liquid
  • B01D 35/02 - Filters adapted for location in special places, e.g. pipe-lines, pumps, stop-cocks
  • B01D 63/08 - Flat membrane modules
  • C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
  • C12M 3/08 - Apparatus for tissue disaggregation
  • C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • F04B 43/04 - Pumps having electric drive
  • G01N 1/28 - Preparing specimens for investigation

12.

NATURAL GAS CONVERSION TO CHEMICALS AND POWER WITH MOLTEN SALTS

      
Document Number 03099562
Status Pending
Filing Date 2019-05-14
Open to Public Date 2019-11-28
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Mcfarland, Eric W.
  • Upham, Ches
  • Palmer, Clarke
  • Su, Shizhao
  • Mannini, Davide
  • Rahimi, Nazanin
  • Kang, Dohyung
  • Metiu, Horia
  • Gordon, Michael

Abstract

A reaction process comprises feeding a feed stream comprising a hydrocarbon into a vessel, reacting the feed stream in the vessel, producing solid carbon and a gas phase product based on the contacting of the feed stream with the molten salt mixture, separating the gas phase product from the molten salt mixture, and separating the solid carbon from the molten salt mixture to produce a solid carbon product. The vessel comprises a molten salt mixture, and the molten salt mixture comprises a reactive component.

IPC Classes  ?

  • B01J 19/00 - Chemical, physical or physico-chemical processes in general; Their relevant apparatus
  • B01J 19/28 - Moving reactors, e.g. rotary drums
  • B01J 23/89 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with noble metals

13.

SINGLE CELL MAPPING AND TRANSCRIPTOME ANALYSIS

      
Document Number 03099525
Status Pending
Filing Date 2019-05-21
Open to Public Date 2019-11-28
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Krummel, Matthew
  • Hu, Kenneth Hsueh-Heng

Abstract

Methods of tagging cells with unique oligonucleotide "zipcode" constructs are provided. By these methods and associated compositions, cells in a multicellular structure such as a tissue section can be tagged with a construct, the unique composition of which is associated with the cells position in the multicellular structure. Subsequently, the multicellular structure can be dissociated into single cells and a single cell transcriptome analysis performed, as well as other types of single cell analyses. By preserving positional information in the analyzed single cells, biological processes within the tissue can be mapped. By these methods, the effects of the local environment surrounding a cell on its state and various functions can be elucidated, and intra-tissue processes can be mapped and observed. Likewise, coordinated actions by multiple cells within a tissue can be mapped and tracked over time.

IPC Classes  ?

  • C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
  • B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers

14.

METHODS FOR MICROBIAL IDENTIFICATION IN CLINICAL SPECIMENS BY DIFFERENTIAL RIBOSOMAL RNA PROBE HYBRIDIZATION

      
Document Number 03099741
Status Pending
Filing Date 2019-05-14
Open to Public Date 2019-11-21
Owner
  • MICROBEDX INC. (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Churchill, Bernard
  • Churchman, Scott Adam
  • Haake, David Arnold
  • Halford, Colin Wynn
  • Knauf, Roger
  • Monti, Gabriel

Abstract

A method of identifying a target microbe in a specimen and including the steps of a) obtaining a specimen, b) lysing the specimen to release a plurality of rRNA molecules from one or more first target microbes in the specimen; c) contacting the specimen with a plurality of first oligonucleotide probe sets configured to selectively bind to rRNA molecules released from the target microbe thereby forming a plurality of first hybridized complexes, each first hybridized complex including one first capture probe and one first detector probe and one of the plurality of rRNA molecules, and d) analyzing the first hybridized complexes to identify a first target microbe in the specimen.

IPC Classes  ?

  • C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
  • C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
  • C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions

15.

IN VIVO BLOOD FILTRATION MEMBRANES AND DEVICES

      
Document Number 03100543
Status Pending
Filing Date 2019-05-17
Open to Public Date 2019-11-21
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Roy, Shuvo
  • Chui, Benjamin W.
  • Wright, Nathan

Abstract

Filtration membrane with improved mechanical stability and increased resistance to pressure is provided. The filtration membrane is useful for in vivo implantable filtration devices, such as, an artificial kidney. In vivo implantable filtration devices are also provided.

IPC Classes  ?

  • A61M 1/14 - Dialysis systems; Artificial kidneys; Blood oxygenators

16.

COMPOSITIONS AND METHODS FOR MODIFYING REGULATORY T CELLS

      
Document Number 03099401
Status Pending
Filing Date 2019-05-07
Open to Public Date 2019-11-14
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Marson, Alexander
  • Bluestone, Jeffrey A.
  • Schumann, Kathrin

Abstract

The disclosure features methods directed to modifying regulatory T (Treg) cell stability by inhibiting the expression of one or more transcription factors and/or inhibiting one or more genes or gene products regulated by the transcription factors. The disclosure also features compositions comprising the Treg cells having modified stability.

IPC Classes  ?

  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • C12N 9/22 - Ribonucleases
  • C12N 15/09 - Recombinant DNA-technology
  • C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

17.

MODIFICATION OF IMMUNE CELLS TO INCREASE ACTIVITY

      
Document Number 03100045
Status Pending
Filing Date 2019-05-13
Open to Public Date 2019-11-14
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Kaufman, Dan
  • Zhu, Huang

Abstract

Compositions, methods of making, and using modified immune cells such as NK cells to treat cancer, viral and microbial infection. The modified CISH -/- NK cells exhibit hypersensitivity to cytokines such as IL-2 and/or IL-15 and maintain expansion and anti-tumor functions.

IPC Classes  ?

  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
  • A61P 31/12 - Antivirals
  • A61P 35/02 - Antineoplastic agents specific for leukemia
  • A61P 37/04 - Immunostimulants

18.

SPIKED PRIMERS FOR ENRICHMENT OF PATHOGEN NUCLEIC ACIDS AMONG BACKGROUND OF NUCLEIC ACIDS

      
Document Number 03097938
Status Pending
Filing Date 2019-05-03
Open to Public Date 2019-11-07
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Chiu, Charles
  • Deng, Xianding

Abstract

Methods, compositions and kits for detection of a taxon of pathogenic microorganisms in a sample are provided. Also provided are methods, compositions and kits for detecting taxons of pathogenic microorganisms present in low titers in a sample. Compositions, methods and kits for detection of pathogenic co-infections are also provided.

IPC Classes  ?

  • C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
  • C12Q 1/686 - Polymerase chain reaction [PCR]
  • C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
  • C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

19.

SLC26A3 INHIBITORS AND USE THEREOF

      
Document Number 03098293
Status Pending
Filing Date 2019-04-25
Open to Public Date 2019-10-31
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Verkman, Alan S.
  • Cil, Onur
  • Haggie, Peter M.

Abstract

Provided herein are inhibitors of SLC26A3, which is an anion (CV, HCO3, oxalate) exchanger expressed in intestinal epithelial cells. SLC26A3 inhibitors have potential utility for treatment of constipation including chronic idiopathic constipation (CIC), opioid-induced constipation (OIC), constipation-predominant irritable bowel syndrome (IBS-C), cystic fibrosis-associated constipation, meconium ileus, distal intestinal obstruction syndrome, calcium oxalate kidney stone disease, enteric hyperoxaluria and primary hyperoxalurias.

IPC Classes  ?

  • A61K 31/37 - Coumarins, e.g. psoralen
  • A61K 31/4164 - 1,3-Diazoles
  • A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
  • A61P 1/10 - Laxatives
  • C07D 311/42 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4

20.

SUSTAINED RELEASE FORMULATION FOR LOCAL DELIVERY OF CDK9 INHIBITORS

      
Document Number 03098129
Status Pending
Filing Date 2019-04-23
Open to Public Date 2019-10-31
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • TESIO PHARMACEUTICALS, INC. (USA)
Inventor
  • Haudenschild, Dominik R.
  • Yik, Jasper H.N.
  • Lewis, Jamal S.
  • Yarbrough, Tom

Abstract

The present disclosure describes a novel sustained-release formulation for the local delivery of CDK9 inhibitors.

IPC Classes  ?

  • A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
  • A61K 9/52 - Sustained or differential release type
  • A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
  • A61K 31/453 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
  • A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
  • A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

21.

METHODS AND COMPOSITIONS FOR HAIR GROWTH BY ACTIVATING AUTOPHAGY

      
Document Number 03096543
Status Pending
Filing Date 2019-04-15
Open to Public Date 2019-10-24
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Huang, Jing
  • Chai, Min
  • Reue, Karen Lynn
  • Vergnes, Laurent
  • Crooks, Gay Miriam
  • De Barros, Stephanie Cochonneau
  • Jiang, Meisheng

Abstract

Disclosed are methods improving or stimulating hair regeneration; treating, inhibiting, or reducing hair loss; improving or stimulating hair growth; treating, inhibiting, or reducing pigmentation loss; and/or improving or stimulating pigmentation production in a subject with one or more autophagy inducing agents.

IPC Classes  ?

  • A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
  • A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
  • A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
  • A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
  • A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
  • A61Q 7/00 - Preparations for affecting hair growth

22.

COMPOSITIONS AND METHODS FOR GENE EDITING

      
Document Number 03096713
Status Pending
Filing Date 2019-04-19
Open to Public Date 2019-10-24
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Chen, Jin
  • Gilbert, Luke
  • Nunez, James
  • Weissman, Jonathan

Abstract

Provided herein are, inter alia, compositions and methods for manipulation of genomes of living organisms.

IPC Classes  ?

  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12N 15/117 - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
  • C12N 9/22 - Ribonucleases
  • C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

23.

PAK4 INHIBITORS AND METHODS OF USE

      
Document Number 03097543
Status Pending
Filing Date 2019-04-16
Open to Public Date 2019-10-24
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Ribas, Antoni
  • Rodriguez, Gabriel Abril
  • Grasso, Catherine
  • Torrejon, Davis Y.

Abstract

Disclosed herein are methods of treating cancer in a subject, comprising: administering at least one PAK4 inhibitor to the subject; and in certain embodiments administering at least one immunostimulatory agent to the subject. In some aspects, the immunostimulatory agent can be a checkpoint inhibitor. In certain aspects the checkpoint inhibitor can be an anti-PDl antibody.

IPC Classes  ?

  • A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
  • A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
  • A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61P 35/02 - Antineoplastic agents specific for leukemia
  • A61P 35/04 - Antineoplastic agents specific for metastasis
  • C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
  • C12N 9/99 - Enzyme inactivation by chemical treatment

24.

FUSION PROTEINS AND FUSION RIBONUCLEIC ACIDS FOR TRACKING AND MANIPULATING CELLULAR RNA

      
Document Number 03097857
Status Pending
Filing Date 2019-04-22
Open to Public Date 2019-10-24
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Yeo, Eugene
  • Tan, Frederick

Abstract

Described herein are compositions, systems, methods, and kits utilizing RNA binding protein fusions, such as CRISPR-Cas protein fusions comprising a guide nucleotide sequence-programmable RNA binding protein, and a translation modifier protein. Also, described herein are compositions, systems, methods, and kits utilizing CRISPR-Cas associated RNA fusions comprising a guide nucleotide sequence-programmable RNA and an internal ribosome entry site (IRES). The compositions, systems, methods, and kits described herein are useful to upregulate or downregulate mRNA translation.

IPC Classes  ?

  • C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
  • C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N 15/90 - Stable introduction of foreign DNA into chromosome

25.

REPROGRAMMING OF NON-NEURONAL CELLS INTO NEURONS AND METHODS AND COMPOSITIONS TO TREAT NEURODEGENERATIVE DISEASES AND DISORDERS

      
Document Number 03096691
Status Pending
Filing Date 2019-04-11
Open to Public Date 2019-10-17
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Fu, Xiang-Dong
  • Qian, Hao

Abstract

Provided herein is a method of reprogramming a non-neuronal cell to a neuron. Aspects of the present disclosure relate to using cell reprogramming agent suppresses the expression or activity of PTB to convert a non-neuronal cell into a neuron. Also provided herein is a method of treating neurodegenerative disease by reprogramming non-neuronal cells in vivo to functional neurons.

IPC Classes  ?

  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • C12N 5/079 - Neural cells
  • C12N 5/0793 - Neurons
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof

26.

COGNITION AND MEMORY ENHANCEMENT VIA MULTIPLE ODORANT STIMULATION

      
Document Number 03096846
Status Pending
Filing Date 2019-04-12
Open to Public Date 2019-10-17
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor Leon, Michael

Abstract

Disclosed herein are methods, kits, and devices for improving cognitive function and memory through olfactory stimulation. In some embodiments, olfactory stimulation is performed by releasing one or more scents according to an olfactory stimulation regimen or schedule. The methods, kits and devices described herein can provide a large impact on cognition with minimal effort and cost. They can be used widely and effectively among older adults, children, and other populations in need of improved cognitive performance.

IPC Classes  ?

  • A61M 21/00 - Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
  • A61L 9/12 - Apparatus, e.g. holders, therefor
  • A61L 9/14 - Disinfection, sterilisation or deodorisation of air using sprayed or atomised substances

27.

DETECTION OF PHOSPHOKINASE SIGNATURES

      
Document Number 03096871
Status Pending
Filing Date 2019-04-12
Open to Public Date 2019-10-17
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Coppe, Jean-Philippe
  • Van 'T Veer, Laura J.

Abstract

The disclosure provides methods and compositions for determining the kinase activity profile of a biological sample, e.g., that contains multiple kinases.

IPC Classes  ?

  • C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
  • C12N 9/10 - Transferases (2.)
  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

28.

HIGH TEMPERATURE OXIDATION RESISTANT CO-BASED GAMMA/GAMMA PRIME ALLOY DMREF-CO

      
Document Number 03094330
Status Pending
Filing Date 2019-04-04
Open to Public Date 2019-10-10
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Pollock, Tresa M.
  • Stewart, Colin A.
  • Murray, Sean P.
  • Levi, Carlos G.

Abstract

A senes of alloys of Co, Ni, Al, W, Ta, and Cr, wherein the alloy comprises a solid solution of gamma and gamma prime alloy phases, the Ni content is greater than 25% at.%, the Al content is greater than 10 at, %, the Cr content is greater than 2 at.%, and the Nr Co ratio is between 0.5 and 1.5. In one or more examples, the alloy further comprises one or more of C, B, and a reactive element metal. Embodiments of the alloy simultaneously possess a high solvus temperature, a high fraction of the strengthening ?'-L12 phase, good oxidation resistance and highly favorable solidification characteristics.

IPC Classes  ?

  • C22C 1/03 - Making non-ferrous alloys by melting using master alloys
  • C22C 21/02 - Alloys based on aluminium with silicon as the next major constituent
  • H04M 1/02 - Constructional features of telephone sets

29.

METHODS OF TREATING GLIOBLASTOMAS

      
Document Number 03095757
Status Pending
Filing Date 2019-04-04
Open to Public Date 2019-10-10
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Lim, Wendell A.
  • Okada, Hideho
  • Roybal, Kole T.
  • Choe, Joseph H.
  • Watchmaker, Payal B.

Abstract

Methods are provided for treating a subject for glioblastoma, including e.g., an EGFRvIII negative glioblastoma. The methods of the present disclosure involve administering to a subject a molecular circuit that includes a binding triggered transcriptional switch (BTTS) that binds to a priming antigen expressed by the subjects glioblastoma multiforme (GBM) that, when bound to the priming antigen, induces one or more encoded therapeutics specific for one or more antigens expressed by the GBM. Nucleic acids containing sequences encoding all or portions of such circuits are also provided, as well as cells, expression cassettes and vectors that contain such nucleic acids. Also provided are kits for practicing the described methods.

IPC Classes  ?

  • A61K 35/14 - Blood; Artificial blood
  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • A61P 35/00 - Antineoplastic agents
  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
  • C07K 14/725 - T-cell receptors
  • C07K 19/00 - Hybrid peptides
  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

30.

TRANS-ANTIGEN TARGETING IN HETEROGENEOUS CANCERS AND METHODS OF USE THEREOF

      
Document Number 03096200
Status Pending
Filing Date 2019-04-04
Open to Public Date 2019-10-10
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Lim, Wendell A.
  • Okada, Hideho
  • Roybal, Kole T.
  • Choe, Joseph H.
  • Williams, Jasper Z.

Abstract

Provided are methods of treating a subject for a heterogeneous cancer. The methods of the present disclosure include integrating at least two antigens expressed heterogeneously in the cancer and/or in the cancer microenvironment, including where the antigens are expressed in trans, i.e., expressed by at least two different cell types. The subject methods will generally involve immune cells into which circuits have been introduced that employ one or more binding triggered transcriptional switches and one or more encoded therapeutics specific for antigens expressed by cancer cells and/or by neighboring non-cancer cells. Nucleic acids containing sequences encoding all or portions of such circuits are also provided, as well as cells, expression cassettes and vectors that contain such nucleic acids. Also provided are kits for practicing the described methods.

IPC Classes  ?

  • A61K 35/12 - Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • A61P 35/00 - Antineoplastic agents
  • C07K 19/00 - Hybrid peptides
  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

31.

METHODS OF TREATING EGFRVIII EXPRESSING GLIOBLASTOMAS

      
Document Number 03096202
Status Pending
Filing Date 2019-04-04
Open to Public Date 2019-10-10
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Lim, Wendell A.
  • Okada, Hideho
  • Roybal, Kole T.
  • Choe, Joseph H.
  • Watchmaker, Payal B.

Abstract

Methods are provided for treating a subject for an EGFRvIII expressing glioblastoma. The methods of the present disclosure involve administering to the subject a molecular circuit that is primed by EGFRvIII to induce one or more encoded therapeutics specific for one or more antigens expressed by the glioblastoma. Nucleic acids containing sequences encoding all or portions of such circuits are also provided, as well as cells, expression cassettes and vectors that contain such nucleic acids. Also provided are kits for practicing the described methods.

IPC Classes  ?

  • A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

32.

HYDROPHOBIC PIGMENT MODIFICATION

      
Document Number 03038740
Status Pending
Filing Date 2019-04-02
Open to Public Date 2019-10-05
Owner
  • ROHM AND HAAS COMPANY (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Bohling, James C.
  • Katz, Alexander
  • Mishra, Manish
  • Radke, Clayton J.
  • Van Dyk, Antony K.

Abstract

The present invention is a composition comprising an aqueous dispersion of metal oxide pigment particles coated with a polymer comprising structural units of an alkyltrihydroxysilane or a salt thereof and a dialkyldihydroxysilane or a salt thereof. The composition of the present invention provides hydrophobicity to pigment particles, thereby imparting water resistance, and allows for high loadings of pigment in water without increased viscosity.

IPC Classes  ?

33.

CDP PROTEIN SECRETION INHIBITORS

      
Document Number 03095471
Status Pending
Filing Date 2019-03-29
Open to Public Date 2019-10-03
Owner
  • KEZAR LIFE SCIENCES (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Mcminn, Dustin
  • Taunton, John William
  • Sharp, Phillip Patrick

Abstract

rovided herein are compounds that inhibit protein secretion, e.g., via inhibition of Sec61. Also provided are compositions of the inhibitor compounds, and methods of using these inhibitors. The compounds disclosed herein can be used, e.g., for the treatment of cancer, arthritis, and/or inflammation.

IPC Classes  ?

  • C07K 11/02 - Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins
  • A61K 38/15 - Depsipeptides; Derivatives thereof

34.

VIRUS BIORESISTORS

      
Document Number 03095621
Status Pending
Filing Date 2019-03-29
Open to Public Date 2019-10-03
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • PHAGETECH, INC. (USA)
Inventor
  • Penner, Reginald M.
  • Ogata, Alana F.
  • Bhasin, Apurva
  • Weiss, Gregory A.
  • Tam, Phillip
  • Briggs, Jeffrey Scott
  • Yap-True, Marie
  • Attar, Aisha
  • Patterson, Shae Victoria

Abstract

Provided herein are, inter alia, biosensors and electrochemical cells comprising electronically conductive polymers and viral particles; diagnostic kits; and methods of detecting compounds in samples.

IPC Classes  ?

  • C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
  • C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
  • C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
  • G01N 27/02 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
  • G01N 27/22 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating capacitance
  • G01N 27/28 - Electrolytic cell components
  • G01N 27/416 - Systems
  • G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

35.

LFA3 VARIANTS AND COMPOSITIONS AND USES THEREOF

      
Document Number 03094756
Status Pending
Filing Date 2019-03-25
Open to Public Date 2019-10-03
Owner
  • PFIZER INC. (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Crellin, Natasha Kay
  • Ely, Lauren Kate
  • Reyes, Jason Robles
  • Ho, Chia Chi
  • Bluestone, Jeffrey A.
  • Trotta, Eleonora
  • Tang, Qizhi

Abstract

The invention provides LFA3 polypeptide molecules, e.g., variant LFA3 fusion polypeptide molecules. The invention includes uses, and associated methods of using the LFA3 polypeptide molecules.

IPC Classes  ?

  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants

36.

METHOD AND SYSTEM FOR DIGITAL STAINING OF LABEL-FREE FLUORESCENCE IMAGES USING DEEP LEARNING

      
Document Number 03095739
Status Pending
Filing Date 2019-03-29
Open to Public Date 2019-10-03
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Ozcan, Aydogan
  • Rivenson, Yair
  • Wang, Hongda
  • Wei, Zhensong

Abstract

A deep learning-based digital staining method and system are disclosed that enables the creation of digitally/virtually-stained microscopic images from label or stain-free samples based on autofluorescence images acquired using a fluorescent microscope. The system and method have particular applicability for the creation of digitally/virtually-stained whole slide images (WSIs) of unlabeled/unstained tissue samples that are analyzes by a histopathologist. The methods bypass the standard histochemical staining process, saving time and cost. This method is based on deep learning, and uses, in one embodiment, a convolutional neural network trained using a generative adversarial network model to transform fluorescence images of an unlabeled sample into an image that is equivalent to the brightfield image of the chemically stained-version of the same sample. This label-free digital staining method eliminates cumbersome and costly histochemical staining procedures and significantly simplifies tissue preparation in pathology and histology fields.

IPC Classes  ?

  • G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
  • G06T 7/10 - Segmentation; Edge detection
  • G06T 7/11 - Region-based segmentation
  • G06T 1/00 - General purpose image data processing
  • G06T 1/20 - Processor architectures; Processor configuration, e.g. pipelining
  • G06T 1/40 - Neural networks
  • G06T 7/00 - Image analysis

37.

INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE

      
Document Number 03092345
Status Pending
Filing Date 2019-03-13
Open to Public Date 2019-09-19
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Sheppard, Dean
  • Sundaram, Aparna
  • Degrado, William F.
  • Jo, Hyunil

Abstract

Disclosed herein, inter alia, are inhibitors of integrin alpha 2 beta 1 and methods of using the same.

IPC Classes  ?

  • C07C 275/24 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
  • A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
  • A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
  • A61K 31/401 - Proline; Derivatives thereof, e.g. captopril
  • A61K 31/426 - 1,3-Thiazoles
  • A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
  • A61K 31/44 - Non-condensed pyridines; Hydrogenated derivatives thereof
  • A61P 11/06 - Antiasthmatics
  • C07D 213/81 - Amides; Imides

38.

BIOREACTIVE COMPOSITIONS AND METHODS OF USE THEREOF

      
Document Number 03093377
Status Pending
Filing Date 2019-03-08
Open to Public Date 2019-09-12
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Wang, Lei
  • Wang, Nanxi

Abstract

Provided herein are, inter alia, non-toxic, bioreactive unnatural amino acids and methods of using same.

IPC Classes  ?

  • C12N 9/00 - Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
  • C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
  • A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
  • A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
  • C07K 1/113 - General processes for the preparation of peptides by chemical modification of precursor peptides without change of the primary structure
  • C12N 15/52 - Genes encoding for enzymes or proenzymes
  • C12P 21/00 - Preparation of peptides or proteins

39.

COMBINATION TREATMENT OF CHEMORESISTANT CANCERS

      
Document Number 03093568
Status Pending
Filing Date 2019-03-11
Open to Public Date 2019-09-12
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Kipps, Thomas
  • Zhang, Suping
  • Ghia, Emanuela M.

Abstract

There are provided, inter alia, compositions and methods for treatment of chemoresistant cancer (breast cancer). The methods include administering to a subject in need a therapeutically effective amount of a chemotherapeutic agent and a ROR- 1 antagonist. Further provided are pharmaceutical compositions including chemotherapeutic agent, ROR- 1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the chemotherapeutic agent is paclitaxel and the ROR- 1 antagonist is cirmtuzumab.

IPC Classes  ?

  • C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61P 35/04 - Antineoplastic agents specific for metastasis

40.

A MODULAR SYSTEM FOR GENE AND PROTEIN DELIVERY BASED ON AAV

      
Document Number 03092451
Status Pending
Filing Date 2019-02-28
Open to Public Date 2019-09-06
Owner
  • UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Byrne, Leah
  • Ozturk, Bilge Esin
  • Day, Timothy

Abstract

In one embodiment, the invention provides an Adeno-Associated Virus (AAV) comprising an exterior surface, which surface comprises one or more peptide tags that form a bond with a binding-partner, wherein the AAV is a live virus. In another embodiment, the invention provides a conjugate comprising at least one such AAV and at least one polypeptide comprising a first domain which is the binding-partner for the tag and a second domain, which is a bioactive polypeptide. In another embodiment, the invention provides a conjugate comprising at least one such AAV (first AAV) and at least one second AAV, which second AAV comprises a second exterior surface, which second exterior surface comprises at least one binding-partner for the tag or for a third linker molecule, wherein the at least one first AAV and the at least one second AAV are bound.

IPC Classes  ?

  • A61K 35/76 - Viruses; Subviral particles; Bacteriophages
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
  • C12N 9/22 - Ribonucleases
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof
  • C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

41.

CAR-T CELLS AND AUTOIMMUNE DISEASES

      
Document Number 03090891
Status Pending
Filing Date 2019-02-11
Open to Public Date 2019-08-15
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Bluestone, Jeffrey A.
  • Raffin, Caroline

Abstract

Chimeric antigen receptor (CAR)-expressing Tregs specifically target an antigen present in the joint of RA patients to induce a localized and effective immunosuppressive response.

IPC Classes  ?

  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C07K 14/725 - T-cell receptors
  • G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

42.

REDOX AND ION-ADSORBTION ELECTRODES AND ENERGY STORAGE DEVICES

      
Document Number 03089753
Status Pending
Filing Date 2019-01-28
Open to Public Date 2019-08-08
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • El-Kady, Maher F.
  • Kaner, Richard B.
  • Mousavi, Mir Fazlollah

Abstract

Provided herein are energy storage devices comprising a first electrode comprising a layered double hydroxide, a conductive scaffold, and a first current collector; a second electrode comprising a hydroxide and a second current collector; a separator; and an electrolyte. In some embodiments, the specific combination of device chemistry, active materials, and electrolytes described herein form storage devices that operate at high voltage and exhibit the capacity of a battery and the power performance of supercapacitors in one device.

IPC Classes  ?

  • H01M 4/32 - Nickel oxide or hydroxide electrodes
  • H01G 11/28 - Electrodes characterised by their structure, e.g. multi-layered, porosity or surface features arranged or disposed on a current collector; Layers or phases between electrodes and current collectors, e.g. adhesives
  • H01G 11/50 - Electrodes characterised by their material specially adapted for lithium-ion capacitors, e.g. for lithium-doping or for intercalation
  • H01G 11/86 - Processes for the manufacture of hybrid or EDL capacitors, or components thereof specially adapted for electrodes
  • H01M 4/52 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron
  • H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers

43.

THERAPIES AND METHODS TO TREAT TLR2-MEDIATED DISEASES AND DISORDERS

      
Document Number 03089709
Status Pending
Filing Date 2019-01-29
Open to Public Date 2019-08-01
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Witztum, Joseph L.
  • Tsimikas, Sotirios
  • Que, Xuchu

Abstract

The disclosure provides for methods and treatments of TLR2- mediated diseases and disorders comprising administering an antibody, antibody fragment, or polypeptide that binds to and inhibits the biological activity of oxidized phospholipids.

IPC Classes  ?

  • C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere

44.

METHOD AND APPARATUS FOR EXTENDING DEPTH OF FIELD DURING FLUORESCENCE MICROSCOPY IMAGING

      
Document Number 03089228
Status Pending
Filing Date 2019-01-28
Open to Public Date 2019-08-01
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Fereidouni, Farzad
  • Levenson, Richard M.

Abstract

The disclosed embodiments relate to a system that performs microscopy imaging with an extended depth of field. This system includes a stage for holding a sample, and a light source for illuminating the sample, wherein the light source produces ultraviolet light with a wavelength in the 230 nm to 300 nm range to facilitate microscopy with ultraviolet surface excitation (MUSE) imaging. The system also includes an imaging device, comprising an objective that magnifies the illuminated sample, and a sensor array that captures a single image of the magnified sample. The system also includes a controller, which controls the imaging device and/or the stage to scan a range of focal planes for the sample during an acquisition time for the single image. The system additionally includes an image-processing system, which processes the single image using a deconvolution technique to produce a final image with an extended depth of field.

IPC Classes  ?

  • G01N 21/00 - Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
  • G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
  • G02B 7/04 - Mountings, adjusting means, or light-tight connections, for optical elements for lenses with mechanism for focusing or varying magnification

45.

METHODS AND COMPOSITIONS FOR TREATMENT OF ANGIOGENIC DISORDRES USING ANTI-VEGF AGENTS

      
Document Number 03089481
Status Pending
Filing Date 2019-01-25
Open to Public Date 2019-08-01
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor Ferrara, Napoleone

Abstract

Provided are methods and compositions for treatment of angiogenic disorders using anti-VEGF agents. The anti-VEGF agents comprise VEGF binding domains and have the ability to bind vitreous. Provided are exemplary embodiments of Fc-IgG fusion proteins with VEGF binding domains with strong heparin-binding characteristics, strong inhibition of VEGF mitogenic activity, and improved pharmacokinetics, namely longer half-lives of the anti-VEGF agents and consequently less frequent dosing.

IPC Classes  ?

  • A61K 38/00 - Medicinal preparations containing peptides
  • C07K 14/71 - Receptors; Cell surface antigens; Cell surface determinants for growth regulators

46.

ACIDIC NANOPARTICLES FOR RESTORATION OF AUTOPHAGY

      
Document Number 03088371
Status Pending
Filing Date 2019-01-21
Open to Public Date 2019-07-25
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • TRUSTEES OF BOSTON UNIVERSITY (USA)
Inventor
  • Shirihai, Orian
  • Grinstaff, Mark
  • Zeng, Jialiu

Abstract

In various embodiments novel biodegradable acid-activated acid releasing nanoparticles (acNPs) are provided that are used as a targeted strategy to manipulate lysosomal acidity and autophagy. These acNPs based, in certain embodiments, on fluorinated polyesters are degraded at pH 6.0 (pH reported in dysfunctional lysosomes), and release component acids that further lower the lysosomal pH, and thereby increasing autophagic flux and cellular function of hepatocytes under LT. The acNPs can serve as a therapeutic in restoring liver-diseases.

IPC Classes  ?

  • A61K 31/765 - Polymers containing oxygen
  • B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
  • A61P 3/00 - Drugs for disorders of the metabolism
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
  • C07C 55/02 - Dicarboxylic acids

47.

METHOD OF GENERATING MONODISPERSE EMULSIONS

      
Document Number 03076911
Status Pending
Filing Date 2018-09-28
Open to Public Date 2019-07-18
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Abate, Adam R.
  • Hatori, Makiko N.
  • Liu, Leqian
  • Kim, Samuel
  • Modavi, Cyrus

Abstract

The methods described herein, referred to as particle-templated emulsification (PTE), provide an improved approach for generating a monodisperse emulsion that encapsulates target particles of interest without requiring the use of a microfluidic device. Monodisperse droplets may be effectively obtained by using monodisperse particles to template the formation of droplets, which can include, e.g., monodisperse single-emulsion droplets, multiple-emulsion droplets, or Giant Unilamellar Vesicles (GUV), without destroying the integrity of the droplets.

IPC Classes  ?

  • B01J 13/02 - Making microcapsules or microballoons
  • C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
  • C12Q 1/6844 - Nucleic acid amplification reactions
  • C12Q 1/6869 - Methods for sequencing
  • C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
  • C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • A61K 9/51 - Nanocapsules

48.

METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS

      
Document Number 03087765
Status Pending
Filing Date 2019-01-07
Open to Public Date 2019-07-11
Owner
  • CHEMOCENTRYX, INC. (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Campbell, James J.
  • Singh, Rajinder
  • Hwang, Samuel
  • Wu, Xuesong

Abstract

The present disclosure provides, inter alia, methods of treating a solid-tumor by administering an effective amount of a Chemokine Receptor 2 (CCR2) antagonist. Also provided herein are methods of reducing the number of macrophages in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In an additional aspect, the current disclosure further provides methods of increasing the number CD8+ T cells in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In some embodiments, the CCR2 antagonist has the formula (I).

IPC Classes  ?

  • A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
  • A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
  • C07D 405/00 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D 405/02 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond

49.

HUMAN ANTIBODIES THAT BIND AND ARE INTERNALIZED BY MESOTHELIOMA AND OTHER CANCER CELLS

      
Document Number 03087058
Status Pending
Filing Date 2018-12-26
Open to Public Date 2019-07-04
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Liu, Bin
  • Bidlingmaier, Scott
  • Su, Yang

Abstract

In certain embodiments internalizing anti-CD146 antibodies and conjugates thereof are provided. It was discovered that anti-CD146 antibodies are capable of targeting both epithelioid and sarcamatous subtypes of mesothelioma cells. In certain embodiments methods of detecting and/or treating mesothelioma are provided.

IPC Classes  ?

  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61P 35/00 - Antineoplastic agents
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

50.

RECOMBINANT IGG FC MULTIMERS FOR THE TREATMENT OF NEUROMYELITIS OPTICA

      
Document Number 03085385
Status Pending
Filing Date 2018-12-14
Open to Public Date 2019-06-20
Owner
  • CSL BEHRING LENGNAU AG (Canada)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Spirig, Rolf
  • Baz Morelli, Adriana
  • Verkman, Alan
  • Tradtrantip, Lukmanee

Abstract

This disclosure provides the use of recombinant IgG Fc multimers for the treatment of neuromyelitis optica (NMO), and methods of treating NMO by administering such multimers.

IPC Classes  ?

  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K 16/46 - Hybrid immunoglobulins

51.

HYDROPHOBIC PIGMENT MODIFICATION

      
Document Number 03027783
Status Pending
Filing Date 2018-12-17
Open to Public Date 2019-06-19
Owner
  • DOW GLOBAL TECHNOLOGIES LLC (USA)
  • ROHM AND HAAS COMPANY (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Bohling, James C.
  • Guo, Yijun
  • Katz, Alexander
  • Mishra, Manish
  • Radke, Clayton J.
  • Roper, John A., Iii
  • Van Dyk, Antony K.

Abstract

The present invention is a composition comprising an aqueous dispersion of metal oxide pigment particles coated with a polymer comprising structural units of an alkyltrihydroxysilane or a salt thereof. The composition of the present invention provides hydrophobicity to pigment particles, thereby imparting water resistance, and allows for high loadings of pigment in water without increased viscosity.

IPC Classes  ?

52.

ASSAYS FOR DETECTION OF ACUTE LYME DISEASE

      
Document Number 03082837
Status Pending
Filing Date 2018-11-27
Open to Public Date 2019-06-06
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • THE JOHNS HOPKINS UNIVERSITY (USA)
Inventor
  • Chiu, Charles Y.
  • Soloski, Mark J.
  • Aucott, John N.
  • Bouquet, Jerome

Abstract

The present disclosure relates to measuring gene expression of cells of a blood sample obtained from a mammalian subject suspected of having a tick-borne disease. In particular, the present disclosure provides tools for determining whether a human subject has acute Lyme disease by transcriptome profiling a peripheral blood mononuclear cell sample from the subject.

IPC Classes  ?

  • C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
  • C12Q 1/6834 - Enzymatic or biochemical coupling of nucleic acids to a solid phase
  • G16B 25/00 - ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

53.

METHODS FOR CONDUCTIVE ADHESIVES BASED ON GRAPHENE AND APPLICATIONS THEREOF

      
Document Number 03083254
Status Pending
Filing Date 2018-11-29
Open to Public Date 2019-06-06
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • NANOTECH ENERGY, INC. (USA)
Inventor
  • El-Kady, Maher F.
  • Mohamed, Nahla
  • Kavanaugh, Jack
  • Kaner, Richard B.

Abstract

The present disclosure relates to conductive adhesives and inks. The disclosed conductive adhesives include glues and epoxies, based on graphene and graphene/carbon composites and the methods of manufacture thereof, such conductive adhesives exhibiting excellent conductivity, thermal properties, durability, low curing temperatures, mechanical flexibility, and reduced environmental impact. Further, adhesives with conductive additives such as silver nanowires and the methods of production thereof are disclosed herein.

IPC Classes  ?

  • C08K 5/00 - Use of organic ingredients
  • C09J 4/06 - Adhesives based on organic non-macromolecular compounds having at least one polymerisable carbon-to-carbon unsaturated bond in combination with a macromolecular compound other than an unsaturated polymer of groups
  • C09J 133/06 - Homopolymers or copolymers of esters of esters containing only carbon, hydrogen and oxygen, the oxygen atom being present only as part of the carboxyl radical

54.

BIOFOULING RESISTANT COATINGS AND METHODS OF MAKING AND USING THE SAME

      
Document Number 03083976
Status Pending
Filing Date 2018-11-30
Open to Public Date 2019-06-06
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • HYDROPHILIX, INC. (USA)
Inventor
  • Chen, Dayong
  • Mcverry, Brian T.
  • Rao, Ethan
  • Polasko, Alexandra L.
  • Kaner, Richard B.

Abstract

Disclosed herein are compositions to use in biofouling-resistant coatings, biofouling-resistant coatings, methods of making biofouling-resistant coatings, biofouling-resistant devices, and methods of making biofouling-resistant devices.

IPC Classes  ?

55.

COMPOUNDS AND METHODS FOR HEMATOPOIETIC REGENERATION

      
Document Number 03084491
Status Pending
Filing Date 2018-11-29
Open to Public Date 2019-06-06
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Chute, John P.
  • Jung, Michael E.
  • Diers, Emelyne
  • Roos, Martina
  • Gim, Hyo Jin

Abstract

The invention relates to compounds that promote hematopoietic regeneration. The invention further relates to methods of promoting hematopoietic regeneration using the novel compounds of the invention.

IPC Classes  ?

  • C07C 225/22 - Compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly-bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
  • A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
  • A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
  • A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
  • A61K 31/402 - 1-aryl-substituted, e.g. piretanide
  • A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
  • A61K 31/44 - Non-condensed pyridines; Hydrogenated derivatives thereof
  • A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
  • A61P 43/00 - Drugs for specific purposes, not provided for in groups
  • C07C 233/11 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
  • C07C 233/36 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
  • C07D 207/333 - Radicals substituted by oxygen or sulfur atoms
  • C07D 213/50 - Ketonic radicals
  • C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
  • C07D 231/56 - Benzopyrazoles; Hydrogenated benzopyrazoles
  • C07D 249/06 - 1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
  • C07D 333/36 - Nitrogen atoms
  • C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

56.

ANTI-CXCR5 ANTIBODIES AND COMPOSITIONS AND USES THEREOF

      
Document Number 03025536
Status Pending
Filing Date 2018-11-28
Open to Public Date 2019-06-01
Owner
  • PFIZER, INC. (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Groth, Rachel
  • Snyder, William Brian
  • Dunn, Robert Joseph
  • Porto, Joseph Dal
  • Karin, Michael
  • Cao, Xianjun

Abstract

The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to CXCR5. The antibodies can be afucosylated and exhibit increased ADCC compared with the otherwise identical fucosylated antibodies. The invention includes uses, and associated methods of using the antibodies.

IPC Classes  ?

  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 15/13 - Immunoglobulins
  • C12P 21/08 - Monoclonal antibodies
  • G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor

57.

ENDONUCLEASE SEXING AND STERILIZATION IN INSECTS

      
Document Number 03083123
Status Pending
Filing Date 2018-11-19
Open to Public Date 2019-05-31
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Kandul, Nikolay P.
  • Akbari, Omar S.

Abstract

Methods of the disclosed precision guided sterile insect technique (pgSIT) include methods for directing male sexing in a genetically modified insect and methods of producing a progeny of genetically modified sterile male insect egg. These methods include integrating at least one nucleic acid sequence into a genome of a first insect, the at least one nucleic acid sequence having at least one first guide polynucleotide targeting a female-essential genomic sequence that is required for female-specific viability, introducing an endonuclease into a second insect, and genetically crossing the first insect and the second insect thereby producing progeny expressing the endonuclease and the at least one nucleic acid sequence. For male sterility a second guide polynucleotide targets a male sterility genomic sequence that is required for male-specific sterility.

IPC Classes  ?

  • A01K 67/033 - Rearing or breeding invertebrates; New breeds of invertebrates
  • C12N 15/09 - Recombinant DNA-technology
  • C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C12N 15/90 - Stable introduction of foreign DNA into chromosome

58.

TYPE V CRISPR/CAS EFFECTOR PROTEINS FOR CLEAVING SSDNAS AND DETECTING TARGET DNAS

      
Document Number 03081937
Status Pending
Filing Date 2018-11-20
Open to Public Date 2019-05-31
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Doudna, Jennifer A.
  • Chen, Janice S.
  • Harrington, Lucas Benjamin
  • Ma, Enbo

Abstract

Provided are compositions and methods for detecting a target DNA (double stranded or single stranded) in a sample. In some embodiments, a subject method includes: (a) contacting the sample with: (i) a type V CRISPR/Cas effector protein (e.g., a Cas12 protein such as Cas12a, Cas12b, Cas12c, Cas12d, Cas12e); (ii) a guide RNA (comprising a region that binds to the type V CRISPR/Cas effector protein, and a guide sequence that hybridizes with the target DNA); and (iii) a detector DNA that is single stranded (i.e., a "single stranded detector DNA") and does not hybridize with the guide sequence of the guide RNA; and (b) measuring a detectable signal produced by cleavage (by the type V CRISPR/Cas effector protein) of the single stranded detector DNA. Also provided are compositions and methods for cleaving single stranded DNAs (e.g., non-target ssDNAs), e.g., inside of a cell.

IPC Classes  ?

  • C12N 9/22 - Ribonucleases
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof
  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

59.

FORCE SENSOR CLEAVAGE DOMAIN CONTAINING CHIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF

      
Document Number 03082782
Status Pending
Filing Date 2018-11-15
Open to Public Date 2019-05-23
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
  • Choe, Joseph H.
  • Langridge, Paul
  • Lim, Wendell A.
  • Roybal, Kole T.
  • Struhl, Gary

Abstract

Provided are chimeric polypeptides which modulate various cellular processes following cleavage of a force sensor cleavage domain, including non-Notch force sensor cleavage domains, induced upon binding of a specific binding member of the chimeric polypeptide with its binding partner. Methods of using force sensor cleavage domain-containing chimeric polypeptides to modulate cellular functions, including e.g., modulation (including induction or repression) of gene expression, are also provided. Nucleic acids encoding the subject chimeric polypeptides and associated expression cassettes and vectors as well as cells that contain such nucleic acids and/or expression cassettes and vectors are provided. Also provided, are methods of monitoring cell-cell signaling and method of treating a subject using the described components, as well as kits for practicing the subject methods.

IPC Classes  ?

  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K 19/00 - Hybrid peptides
  • C12N 5/22 - Human cells
  • C12N 15/62 - DNA sequences coding for fusion proteins

60.

SIMULTANEOUS REACTION AND SEPARATION OF CHEMICALS

      
Document Number 03082819
Status Pending
Filing Date 2018-11-16
Open to Public Date 2019-05-23
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Mcfarland, Eric W.
  • Upham, Ches
  • Zeng, Jiren
  • Palmer, Clarke
  • Su, Shizhao
  • Mannini, Davide
  • Kang, Dohyung
  • Rahimi, Nazanin
  • Metiu, Horia
  • Gordon, Michael

Abstract

The reaction rate of hydrocarbon pyrolysis can be increased to produce solid carbon and hydrogen by the use of molten materials which have catalytic functionality to increase the rate of reaction and physical properties that facilitate the formation and contamination-free separation of the solid carbon. Processes, materials, reactor configurations, and conditions are disclosed whereby methane and other hydrocarbons can be decomposed at high reaction rates into hydrogen gas and carbon products without any carbon oxides in a single reaction step. The process also makes use of specific properties of selected materials with unique solubilities and/ or wettability of products into (and/or by) the molten phase to facilitate generation of purified products and increased conversion in more general reactions.

IPC Classes  ?

  • B01J 8/04 - Chemical or physical processes in general, conducted in the presence of fluids and solid particles; Apparatus for such processes with stationary particles, e.g. in fixed beds the fluid passing successively through two or more beds

61.

TREATMENT OF OPIOID USE DISORDER, OPIOID WITHDRAWAL SYMPTOMS AND CHRONIC PAIN

      
Document Number 03082892
Status Pending
Filing Date 2018-11-15
Open to Public Date 2019-05-23
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Heinzerling, Keith G.
  • Briones, Marisa S.
  • Deyoung, Dustin Z.

Abstract

The current methods and compositions provide for a novel and effective therapeutic method for treating opioid use disorder, opioid withdrawal symptoms and/or chronic pain. Accordingly, certain aspects of the disclosure relate to a method for treating opioid use disorder, opioid withdrawal symptoms and/or chronic pain in a subject, the method comprising administering at least one purified cannabinoid compound and a partial opioid agonist. In some embodiments, the method comprises administering a composition comprising cannabidiol and buprenorphine.

IPC Classes  ?

  • A61K 31/05 - Phenols
  • A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

62.

COMPOSITIONS AND METHODS FOR ENHANCING VISUAL FUNCTION

      
Document Number 03080146
Status Pending
Filing Date 2018-11-13
Open to Public Date 2019-05-19
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor Isacoff, Ehud Y.

Abstract

The present disclosure provides a method of restoring or enhancing visual function in an individual, the method comprising administering to the individual a nucleic acid comprising a nucleotide sequence encoding one or more of a medium wavelength cone opsin (MW-opsin), a long wavelength cone opsin (LW-opsin), and a short wavelength cone opsin (SW-opsin). One or more of the MW-opsin, LW-opsin, and SW-opsin is expressed in a retinal cell in the individual, thereby restoring or enhancing visual function.

IPC Classes  ?

  • C12N 15/86 - Viral vectors
  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61P 27/02 - Ophthalmic agents
  • C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
  • C07K 19/00 - Hybrid peptides
  • C12N 15/12 - Genes encoding animal proteins
  • C12N 15/62 - DNA sequences coding for fusion proteins
  • C12N 15/864 - Parvoviral vectors

63.

METAL BORIDES AND USES THEREOF

      
Document Number 03084364
Status Pending
Filing Date 2018-11-07
Open to Public Date 2019-05-16
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Turner, Christopher L.
  • Kaner, Richard B.
  • Akopov, Georgiy
  • Yeung, Michael T.

Abstract

Disclosed herein are compounds, methods, and tools which comprise tungsten borides and mixed transition metal borides.

IPC Classes  ?

64.

NON-CODING RNA FOR DETECTION OF CANCER

      
Document Number 03082391
Status Pending
Filing Date 2018-11-09
Open to Public Date 2019-05-16
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor Goodarzi, Hani

Abstract

The present disclosure relates generally to detection of non-coding RNAS molecules in a sample or diagnosis of subject based upon detection or quantification of non-coding nucleic acid sequences in a sample, specifically to identify and use of molecular biomarkers for cancer including breast cancer.

IPC Classes  ?

  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

65.

CASZ COMPOSITIONS AND METHODS OF USE

      
Document Number 03080493
Status Pending
Filing Date 2018-10-31
Open to Public Date 2019-05-09
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Doudna, Jennifer A.
  • Burstein, David
  • Chen, Janice S.
  • Harrington, Lucas B.
  • Paez-Espino, David
  • Banfield, Jillian F.

Abstract

Provided are compositions and methods that include one or more of: (1) a "CasZ" protein (also referred to as a CasZ polypeptide), a nucleic acid encoding the CasZ protein, and/or a modified host cell comprising the CasZ protein (and/or a nucleic acid encoding the same); (2) a CasZ guide RNA that binds to and provides sequence specificity to the CasZ protein, a nucleic acid encoding the CasZ guide RNA, and/or a modified host cell comprising the CasZ guide RNA (and/or a nucleic acid encoding the same); and (3) a CasZ transactivating noncoding RNA (trancRNA) (referred to herein as a "CasZ trancRNA"), a nucleic acid encoding the CasZ trancRNA, and/or a modified host cell comprising the CasZ trancRNA (and/or a nucleic acid encoding the same).

IPC Classes  ?

  • C12N 15/09 - Recombinant DNA-technology
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 9/22 - Ribonucleases
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof
  • C12N 15/55 - Hydrolases (3)
  • C12N 15/90 - Stable introduction of foreign DNA into chromosome
  • C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

66.

POLYAMINE-APPENDED METAL-ORGANIC FRAMEWORKS FOR CARBON DIOXIDE SEPARATIONS

      
Document Number 03078968
Status Pending
Filing Date 2018-10-30
Open to Public Date 2019-05-09
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
  • EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (USA)
Inventor
  • Weston, Simon C.
  • Falkowski, Joseph M.
  • Long, Jeffrey R.
  • Kim, Eugene J.
  • Martell, Jeffrey D.
  • Milner, Phillip J.
  • Siegelman, Rebecca L.

Abstract

Polyamines with lengths carefully tailored to the framework dimensions are appended to metal -organic frameworks such as Mg2(dobpdc) (dobpdc4- = 4,4'- dioxidobiphenyl-3,3'- dicarboxylate) with the desired loading of one polyamine per two metal sites. The polyamine-appended materials show step-shaped adsorption and desorption profiles due to a cooperative CO2 adsorption/desorption mechanism. Several disclosed polyamine-appended materials exhibit strong ability to capture CO2 from various compositions. Increased stability of amines in the framework has been achieved using high molecular weight polyamine molecules that coordinate multiple metal sites in the framework. The preparation of these adsorbents as well as their characterization are provided.

IPC Classes  ?

  • B01D 53/04 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
  • B01J 20/22 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
  • B01J 20/30 - Processes for preparing, regenerating or reactivating
  • B01J 20/32 - Impregnating or coating
  • B01J 20/34 - Regenerating or reactivating

67.

NOVEL AGENTS TARGETING INHIBITOR OF APOPTOSIS PROTEINS

      
Document Number 03080943
Status Pending
Filing Date 2018-11-01
Open to Public Date 2019-05-09
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Pellecchia, Maurizio
  • Baggio, Carlo
  • Gambini, Luca
  • Udompholkul, Parima

Abstract

Disclosed herein, inter alia, are methods of use and composition of novel inhibitors that target the Smac binding site of a variety of inhibitor of apoptosis proteins that contain a Bir domain, including XIAP, cIAP1, cIAP2, or other IAP proteins.

IPC Classes  ?

  • A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K 38/05 - Dipeptides
  • A61P 35/00 - Antineoplastic agents
  • C07K 5/06 - Dipeptides
  • C07K 5/08 - Tripeptides
  • C07K 5/097 - Tripeptides the first amino acid being heterocyclic, e.g. Pro, His, Trp, e.g. thyroliberin, melanostatin

68.

CALIBRATION FREE IN-VIVO MEASUREMENT OF ANALYTES USING ELECTROCHEMICAL SENSORS

      
Document Number 03081401
Status Pending
Filing Date 2018-10-29
Open to Public Date 2019-05-09
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Plaxco, Kevin
  • Arroyo Curras, Netzahualcoyotl

Abstract

Typical electrochemical sensors measure target-induced changes in current output. Such measures of target binding are inconsistent across individual sensors, and furthermore, signal will drift over time when the sensor is deployed for long periods. These shortcomings can be avoided by the novel use of chronoamperometry to measure current decay kinetics as the indicator of target binding. Current decay lifetimes will vary in a concentration dependent manner, but remain stable across individual sensors and over time, allowing for calibration-free operation. By these methods, aptamer based electrochemical sensors and other sensor types may be deployed in vivo for extended periods of time and will provide accurate measurement of target binding without calibration.

IPC Classes  ?

  • G01N 27/416 - Systems
  • A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
  • A61B 5/1495 - Calibrating or testing in vivo probes

69.

TARGETED REPLACEMENT OF ENDOGENOUS T CELL RECEPTORS

      
Document Number 03080415
Status Pending
Filing Date 2018-10-29
Open to Public Date 2019-05-02
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Roth, Theodore Lee
  • Shifrut, Eric
  • Marson, Alexander
  • Saus, Cristina Puig
  • Ribas, Antoni

Abstract

Provided herein are methods and compositions for editing the genome of a human T cell. In some embodiments, a heterologous T cell receptor (TCR)-ß chain and a heterologous TCR-a chain are inserted into exon 1 of a TCR subunit constant gene in the genome of the T cell.

IPC Classes  ?

  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
  • C07K 14/725 - T-cell receptors
  • C12N 15/09 - Recombinant DNA-technology
  • C12N 15/12 - Genes encoding animal proteins
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C12N 15/90 - Stable introduction of foreign DNA into chromosome

70.

CONTROLLING FUNGAL PATHOGENS USING RNAI-BASED STRATEGY

      
Document Number 03077067
Status Pending
Filing Date 2018-10-04
Open to Public Date 2019-04-25
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor Jin, Hailing

Abstract

The present invention relates to pathogen-resistant plants. In one aspect, plants comprising a heterologous expression cassette are provided, wherein the expression cassette comprises a polynucleotide that inhibits expression of a fungal pathogen gene and wherein the plant has increased resistance to a fungal pathogen or multiple pathogens compared to a control plant lacking the expression cassette. In another aspect, contacting a plant or a plant part with double stranded RNAs or small RNAs that inhibit expression of a fungal target gene or genes from multiple pathogens, wherein the plant has increased resistance to a pathogen or multiple pathogens compared to control plants that has not been contacted with the RNAs. Methods of making and cultivating pathogen-resistant plants are also provided.

IPC Classes  ?

  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant parts; Angiosperms characterised otherwise than by their botanic taxonomy
  • A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
  • A01P 3/00 - Fungicides
  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
  • C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

71.

CONFORMATIONAL EPITOPES IN RESPIRATORY SYNCYTIAL VIRUS G PROTEIN CENTRAL CONSERVED REGION

      
Document Number 03079604
Status Pending
Filing Date 2018-10-12
Open to Public Date 2019-04-18
Owner
  • TRELLIS BIOSCIENCE, LLC (USA)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Dubois, Rebecca
  • Fedechkin, Stas
  • Kauvar, Lawrence M.

Abstract

X-ray crystallography has defined conformational properties of a key functional region of the G protein of respiratory syncytial virus (RSV). Mimics of these epitopes have utility as immunogens, as tools for discovery of antibodies and other monoclonal binding agents, and as pharmacological agents to modulate activity of the host receptors for this viral protein.

IPC Classes  ?

72.

DEEP LEARNING-BASED DIAGNOSIS AND REFERRAL OF OPHTHALMIC DISEASES AND DISORDERS

      
Document Number 03083035
Status Pending
Filing Date 2018-10-12
Open to Public Date 2019-04-18
Owner
  • AI TECHNOLOGIES INC. (Cayman Islands)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Zhang, Kang
  • Hou, Rui
  • Zheng, Lianghong

Abstract

Disclosed herein are systems, methods, devices, and media for carrying out medical diagnosis of ophthalmic diseases and conditions. Deep learning algorithms enable the automated analysis of ophthalmic images to generate predictions of comparable accuracy to clinical experts.

IPC Classes  ?

  • G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
  • A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

73.

IMMUNOMODULATORY OLIGOSACCHARIDES

      
Document Number 03076920
Status Pending
Filing Date 2018-10-04
Open to Public Date 2019-04-11
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Bode, Lars
  • Gordts, Philip

Abstract

The disclosure provides for immunomodulatory oligosaccharides, and uses thereof.

IPC Classes  ?

74.

COMPOSITIONS AND METHODS FOR MODULATING HAIR GROWTH

      
Document Number 03077359
Status Pending
Filing Date 2018-09-28
Open to Public Date 2019-04-04
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Miranda, Matilde
  • Flores, Aimee
  • Lowry, William E.
  • Christofk, Heather R.

Abstract

The present disclosure relates to pharmaceutical compositions containing electron transport chain (ETC) inhibitors, which are capable of promoting hair growth. The disclosure further relates to methods of promoting hair growth or treating conditions or disorders affecting hair growth, such as baldness or alopecia.

IPC Classes  ?

  • A61K 31/365 - Lactones
  • A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
  • A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
  • A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia

75.

COMPOSITIONS AND METHODS FOR TREATING CANCER

      
Document Number 03081548
Status Pending
Filing Date 2018-09-26
Open to Public Date 2019-04-04
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
  • Nathanson, David A.
  • Mai, Wilson X.
  • Jung, Michael E.
  • Clark, Peter M.
  • Cloughesy, Timothy F.
  • Kim, Gyudong
  • Tsang, Jonathan
  • Urner, Lorenz

Abstract

The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating Glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating Glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present dislcsoure also provides methods oadministering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

IPC Classes  ?

  • C07D 239/94 - Nitrogen atoms
  • A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61P 35/00 - Antineoplastic agents
  • C07D 317/48 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
  • C07D 319/18 - Ethylenedioxybenzenes, not substituted on the hetero ring
  • C07D 321/08 - 1, 4-Dioxepines; Hydrogenated 1,4-dioxepines

76.

A GENE THERAPY STRATEGY TO RESTORE ELECTRICAL AND CARDIAC FUNCTION, AND CARDIAC STRUCTURE, IN ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY

      
Document Number 03076227
Status Pending
Filing Date 2018-09-20
Open to Public Date 2019-03-28
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Sheikh, Farah
  • Zhang, Jing

Abstract

Disclosed herein are methods of treating arrhythmogenic right ventricular cardiomyopathy in a subject, comprising administering a gene therapy construct comprising a connexin 43 sequence, wherein as a result of the administration, connexin 43 levels in at least a portion of the heart are increased. Further disclosed are other cardiovascular diseases can be treated with the method.

IPC Classes  ?

  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61P 9/00 - Drugs for disorders of the cardiovascular system
  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
  • C12N 15/12 - Genes encoding animal proteins
  • C12N 15/861 - Adenoviral vectors
  • C12N 15/864 - Parvoviral vectors

77.

AFFINITY-TAGGED PHOTOSWITCHES AND METHODS OF USE THEREOF

      
Document Number 03076976
Status Pending
Filing Date 2018-09-21
Open to Public Date 2019-03-28
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Isacoff, Ehud Y.
  • Trauner, Dirk
  • Broichhagen, Johannes
  • Levitz, Joshua

Abstract

The present disclosure provides a conjugate comprising: a) an affinity agent that specifically binds a target ligand-binding polypeptide; and b) a photoisomerizable regulator comprising: i) a photoisomerizable moiety; and ii) a ligand that binds to the target ligand-binding polypeptide. The present disclosure provides cells comprising a conjugate of the present disclosure. The present disclosure provides methods of using a conjugate of the present disclosure to modulate activity of a target polypeptide, and to modulate activity of a target cell or cell population.

IPC Classes  ?

  • C07K 14/36 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptomyces (G)
  • C07C 245/08 - Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with the two nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings, e.g. azobenzene
  • C07K 14/195 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria

78.

CLAUDIN6 ANTIBODIES AND METHODS OF TREATING CANCER

      
Document Number 03076207
Status Pending
Filing Date 2018-09-18
Open to Public Date 2019-03-21
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Conklin, Dylan
  • Slamon, Dennis
  • O'Brien, Neil
  • Palazzolo, Mike
  • Von Euw, Erika

Abstract

The present disclosure provides antigen-binding proteins which bind to Claudin- 6 (CLDN6). In various aspects, the antigen-binding proteins bind to Extracellular Loop 2 (EL2) of the extracellular domain of CLDN6. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.

IPC Classes  ?

  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo
  • A61P 35/00 - Antineoplastic agents
  • C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
  • C07K 19/00 - Hybrid peptides
  • C12N 15/13 - Immunoglobulins
  • C12N 15/62 - DNA sequences coding for fusion proteins
  • C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
  • C12P 21/08 - Monoclonal antibodies

79.

METHOD AND COMPOSITION FOR TREATING NEUROPATHIC PAIN

      
Document Number 03074587
Status Pending
Filing Date 2018-09-07
Open to Public Date 2019-03-14
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Marsala, Martin
  • Miyanohara, Atsushi
  • Tadokoro, Takahiro

Abstract

The present invention provides a therapy for treating neuropathic pain by subpial administration of small quantities of a composition for spinal segment-specific upregulation of GAD65 (glutamatedecarboxylase) gene and VGAT (vesicular GABA transporter) gene, which is effective for induction of nociceptive effects by potentiating release of vesicular GABA from infected dorsal horn neurons into the synaptic cleft.

IPC Classes  ?

80.

ANTIBODY-MEDIATED DELIVERY OF CAS9 TO MAMMALIAN CELLS

      
Document Number 03075507
Status Pending
Filing Date 2018-09-10
Open to Public Date 2019-03-14
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Corn, Jacob
  • Dewitt, Mark
  • Shams, Arik
  • Foss, Dana V.

Abstract

In certain embodiments a construct for performing gene editing in a mammalian cell is provided. In certain embodiments the construct comprises a targeting moiety that binds a surface marker on a cell (e.g., surface receptor), where the targeting moiety is attached to a complex comprising a class 2 CRISPR/Cas endonuclease complexed with a corresponding CRISPR/Cas guide RNA that hybridizes to a target sequence within the genomic DNA of the cell.

IPC Classes  ?

  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
  • C12N 5/16 - Animal cells
  • C12N 9/22 - Ribonucleases
  • C12N 15/09 - Recombinant DNA-technology
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof
  • C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

81.

DEVICE FOR OPTIMIZATION OF MICROORGANISM GROWTH IN LIQUID CULTURE

      
Document Number 03071462
Status Pending
Filing Date 2018-08-30
Open to Public Date 2019-03-07
Owner
  • MICROBEDX, INC. (Canada)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Perebikovsky, Alexandra
  • Churchill, Bernard
  • Churchman, Scott
  • Haake, David Arnold
  • Halford, Colin Wynn
  • Liu, Yujia
  • Madou, Marc
  • Monti, Gabriel

Abstract

There is described a system for growing a microorganism in liquid culture, the system comprising: a driving apparatus configured to house and oscillate a microfluidic cartridge; and a microfluidic cartridge comprising at least one incubation chamber, such that when the system is in use, the incubation chamber may be oscillated back and forth along an oscillation path using a preferred oscillation protocol. There is also described a method of growing a microorganism in liquid culture, the method comprising disposing a microorganism and suitable growth medium into an incubation chamber; and mixing the microorganism and growth medium by oscillating the incubation chamber back and forth along an oscillation path using a preferred oscillation protocol. There is also described a microfluidic cartridge that may be used to grow microorganisms using the system and methods described above.

IPC Classes  ?

  • A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
  • B01F 7/00 - Mixers with rotary stirring devices in fixed receptacles; Kneaders
  • B01L 1/00 - Enclosures; Chambers
  • B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
  • C12M 1/10 - Apparatus for enzymology or microbiology rotatably mounted
  • C12N 1/38 - Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
  • C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor

82.

ROBOTIC SYSTEMS AND METHODS FOR ROBUSTLY GRASPING AND TARGETING OBJECTS

      
Document Number 03073516
Status Pending
Filing Date 2018-04-04
Open to Public Date 2019-03-07
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Goldberg, Kenneth Yigael
  • Mahler, Jeffrey Brian
  • Matl, Matthew

Abstract

Embodiments are generally directed to generating a training dataset of labelled examples of sensor images and grasp configurations using a set of three-dimensional (3D) models of objects, one or more analytic mechanical representations of either or both of grasp forces and grasp torques, and statistical sampling to model uncertainty in either or both sensing and control. Embodiments can also include using the training dataset to train a function approximator that takes as input a sensor image and returns data that is used to select grasp configurations for a robot grasping or targeting mechanism.

IPC Classes  ?

83.

COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION

      
Document Number 03074139
Status Pending
Filing Date 2018-08-31
Open to Public Date 2019-03-07
Owner
  • OPTIKIRA LLC (Canada)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Keenan, Richard M.
  • Backes, Bradley J.
  • Maly, Dustin J.
  • Reynolds, Charles
  • Whittaker, Ben
  • Knight, Jamie
  • Sutton, Jon
  • Hynd, George
  • Papa, Feroz R.
  • Oakes, Scott A.

Abstract

The present invention provides novel compounds, compositions and methods for treating or preventing an IRE1a-related disease or disorder. In certain embodiments, the disease or disorder is selected from the group consisting of a neurodegenerative disease, a demyelinating disease, cancer, an eye disease, a fibrotic disease, and diabetes.

IPC Classes  ?

  • C07D 487/04 - Ortho-condensed systems
  • A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems

84.

ADENO-ASSOCIATED VIRUS CAPSID VARIANTS AND METHODS OF USE THEREOF

      
Document Number 03059995
Status Pending
Filing Date 2018-08-22
Open to Public Date 2019-03-07
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Schaffer, David V.
  • Ojala, David Stephen
  • Romero, Philip A.

Abstract

The present disclosure provides recombinant adeno-associated virus virions with variant capsid protein, where the recombinant AAV (rAAV) virions exhibit one or more of increased ability to cross neuronal cell barriers, increased infectivity of a neural stem cell, increased infectivity of a neuronal cell, and reduced susceptibility to antibody neutralization, compared to a control AAV, and where the rAAV virions comprise a heterologous nucleic acid. The present disclosure provides methods of delivering a gene product to a neural stem cell or a neuronal cell in an individual. The present disclosure also provides methods of modifying a target nucleic acid present in a neural stem cell or neuronal cell.

IPC Classes  ?

  • C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

85.

MOLECULAR BACTERIOTHERAPY TO CONTROL SKIN ENZYMATIC ACTIVITY

      
Document Number 03072772
Status Pending
Filing Date 2018-08-31
Open to Public Date 2019-03-07
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Gallo, Richard L.
  • Williams, Michael

Abstract

The invention provides a purified polypeptide which inhibits (i) protease production and/or activity of keratinocytes, (ii) inhibits IL-6 production and/or activity of keratinocytes, (iii) inhibits production of phenol soluble modulin alpha 3 from Staphylococcus aureus and/or (iv) inhibits agr production and/or activity by S. aureus. Further provided is a topical formulation comprising the polypeptide. Provided is a recombinant microorganism comprising a vector or polynucleotide encoding the polypeptide. Further provided is a probiotic composition comprising the recombinant microorganism. The invention also provides kits and articles of manufacture comprising the polypeptide and/or the recombinant microorganism.

IPC Classes  ?

  • A61K 35/741 - Probiotics
  • A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61P 17/00 - Drugs for dermatological disorders
  • C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
  • C07K 14/31 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)

86.

OCULAR PHARMACEUTICAL COMPOSITIONS

      
Document Number 03073718
Status Pending
Filing Date 2018-08-24
Open to Public Date 2019-02-28
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Verkman, Alan
  • Levin, Marc H.

Abstract

The disclosure provides, inter alia, topical pharmaceutical compositions comprising active agents, methods for increasing tear production using the topical pharmaceutical compositions, and methods for treating dry eye disorders using the topical pharmaceutical compositions.

IPC Classes  ?

  • A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
  • A61P 27/02 - Ophthalmic agents
  • C07D 251/52 - Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom

87.

MINIATURE IMPLANTABLE WIRELESS PRESSURE SENSOR

      
Document Number 03073198
Status Pending
Filing Date 2018-08-16
Open to Public Date 2019-02-21
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Bachman, Mark
  • Babikian, Sarkis
  • Li, Guann-Pyng

Abstract

A miniature wireless pressure sensor has an inductor and a capacitor. The inductor and the capacitor form a L-C resonator with a resonate frequency. The inductor's inductance is affected by a slidable electro-magnetic element. When an outside pressure is applied onto the element, it causes the element to move and such movement changes the inductance of the inductor. Because of that, the resonate frequency is changed. Therefore, the change in resonate frequency indicates a change in the outside pressure. The L-C resonator is calibrated to correlate with the outside pressure. Such a miniature wireless pressure sensor facilitates the monitoring of physiological pressure in different part of human body such as eyes and cranium.

IPC Classes  ?

88.

METHODS FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING

      
Document Number 03071435
Status Pending
Filing Date 2018-08-20
Open to Public Date 2019-02-21
Owner
  • MICROBEDX, INC. (Canada)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Churchill, Bernard
  • Churchman, Scott Adam
  • Haake, David Arnold
  • Halford, Colin Wynn
  • Knauf, Roger
  • Monti, Gabriel
  • Kido, Horacio
  • Madou, Marc
  • Perebikovsky, Alexandra
  • Liu, Yujia
  • Gussin, Daniel

Abstract

A method for determining the susceptibility of bacteria in a clinical sample comprising urine or an inoculant derived therefrom to an antibiotic agent may include the steps of a) inoculating a test portion of the clinical sample in a medium containing a predetermined concentration of the antibiotic agent; b) inoculating a control portion of the clinical sample in a medium that does not contain the antibiotic agent; c) incubating the test portion for an incubation period; d) incubating the control portion for the incubation period; e) determining a quantity of RNA in the test portion and a quantity of RNA in the control portion at the conclusion of the incubation period that is less than 480 minutes after the completion of step a); and f) determining a susceptibility of the bacteria to the antibiotic agent by comparing the quantity of RNA in the test portion to the quantity of the RNA in the control portion.

IPC Classes  ?

  • C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
  • C12Q 1/18 - Testing for antimicrobial activity of a material
  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

89.

MITIGATION OF ALKALI-SILICA REACTION IN CONCRETE USING READILY-SOLUBLE CHEMICAL ADDITIVES

      
Document Number 03073041
Status Pending
Filing Date 2018-08-13
Open to Public Date 2019-02-21
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
  • YARA INTERNATIONAL ASA (Canada)
  • BASF CORPORATION (Canada)
Inventor
  • Sant, Gaurav N.
  • Falzone, Gabriel D.
  • Oey, Tandre
  • Franke, Wolfram
  • Seiler, Paul
  • La Plante, Erika Callagon

Abstract

A manufacturing method includes: (1) incorporating at least one soluble, calcium, magnesium, or other divalent cation-containing additive into a concrete mixture including aggregates prone to alkali-silica reaction; and (2) curing the concrete mixture to form a concrete product.

IPC Classes  ?

90.

PLATFORM FOR GENERATING SAFE CELL THERAPEUTICS

      
Document Number 03072329
Status Pending
Filing Date 2018-08-07
Open to Public Date 2019-02-14
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Wang, Huawei
  • Klemke, Richard

Abstract

Provided herein are cytoplasts, compositions comprising cytoplasts, methods of using cytoplasts, and methods of treating a subject, such as providing benefits to a healthy or unhealthy subject, or treating or diagnosing a disease or condition in a subject. In some embodiments, methods of treating a subject include: administering to the subject a therapeutically effective amount of a composition comprising a cytoplast. Also, provided herein are compositions (e.g., pharmaceutical compositions) that include a cytoplast. Also, provided herein are kits comprising instructions for using the compositions or methods.

IPC Classes  ?

  • A61K 35/12 - Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans

91.

PROCESS AND DEVICE FOR TEMPERATURE AND PRESSURE CONTROLLED CRYOPRESERVATION

      
Document Number 03072333
Status Pending
Filing Date 2018-08-09
Open to Public Date 2019-02-14
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Rubinsky, Boris
  • Nastase, Gabriel
  • Ukpai, Gideon

Abstract

The disclosure provides processes for temperature and pressure controlled cryopreservation of samples by using isochoric systems.

IPC Classes  ?

  • B65B 17/00 - Other machines, apparatus, or methods for packaging articles or materials

92.

ANTI-CANCER/ANTI-FIBROSIS COMPOUNDS

      
Document Number 03067871
Status Pending
Filing Date 2018-07-31
Open to Public Date 2019-02-07
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
  • METKINE THERAPEUTICS, INC. (Canada)
Inventor
  • Jablons, David M.
  • Xu, Wei
  • You, Liang
  • Liu, Shu
  • Yuan, Shendong
  • Ma, Sunghoon
  • Mac, Morrison

Abstract

This invention provides, among other things, compounds useful for treating diseases such as fibrosis and/or cancer, pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.

IPC Classes  ?

  • C07D 221/10 - Aza-phenanthrenes
  • A61K 31/473 - Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
  • A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
  • A61P 35/00 - Antineoplastic agents
  • C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
  • C07D 401/02 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond

93.

METHODS OF MAKING STREPTOGRAMIN COMPOSITIONS AND THE USE THEREOF

      
Document Number 03070851
Status Pending
Filing Date 2018-07-31
Open to Public Date 2019-02-07
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Seiple, Ian Bass
  • Li, Qi

Abstract

Disclosed herein, inter alia, are methods of making and using streptogramin compositions.

IPC Classes  ?

  • C07D 263/34 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • A61K 31/424 - Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
  • A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
  • A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
  • A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
  • A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
  • A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
  • A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
  • A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
  • A61K 31/695 - Silicon compounds
  • A61P 31/04 - Antibacterial agents
  • C07D 498/08 - Bridged systems
  • C07D 498/18 - Bridged systems
  • C07F 7/10 - Compounds having one or more C—Si linkages containing nitrogen

94.

METHODS FOR LYSIS OF CELLS WITHIN A SAMPLE

      
Document Number 03071367
Status Pending
Filing Date 2018-08-03
Open to Public Date 2019-02-07
Owner
  • MICROBEDX, INC. (Canada)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Monti, Gabriel
  • Halford, Colin Wynn
  • Perebikovsky, Alexandra
  • Liu, Yujia
  • Kido, Horacio
  • Haake, David Arnold
  • Madou, Marc
  • Gussin, Daniel
  • Churchill, Bernard

Abstract

There is described a method for extracting a target chemical compound from a cellular material in a sample. The method comprising the steps of: subjecting the sample to mechanical lysis to cause disruption of a cellular membrane in the cellular material; contacting the sample with an alkaline material to produce a lysate composition comprising the target chemical compound; and recovering the lysate composition from the sample. There is also described a method for producing a lysate composition comprising RNA from a mammalian bodily fluid sample comprising a cellular material. There is also described a method for extracting a nucleic acid from a cellular material in a bodily fluid or an inoculant derived therefrom.

IPC Classes  ?

  • C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
  • C12N 15/11 - DNA or RNA fragments; Modified forms thereof

95.

OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY

      
Document Number 03071835
Status Pending
Filing Date 2018-08-02
Open to Public Date 2019-02-07
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Nguyen, Quyen T.
  • Whitney, Michael A.
  • Hingorani, Dina
  • Tsien, Roger Y.
  • Adams, Stephen

Abstract

The present invention provides methods for guiding preservation of human neurons or human nerves during surgery by administering a fluorescently-labeled peptide that specifically binds to the human neurons or human nerves. The invention further provides human neuron or nerve targeting molecules comprising fluorescently- labeled peptides that specifically bind to human neurons or human nerves and compositions thereof.

IPC Classes  ?

  • A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
  • A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61P 25/00 - Drugs for disorders of the nervous system
  • C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
  • C07K 17/02 - Peptides being immobilised on, or in, an organic carrier
  • G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

96.

METAL-ORGANIC FRAMEWORKS APPENDED WITH CYCLIC DIAMINES FOR CARBON DIOXIDE CAPTURE

      
Document Number 03071434
Status Pending
Filing Date 2018-08-03
Open to Public Date 2019-02-07
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
  • EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (Canada)
Inventor
  • Long, Jeffrey R.
  • Weston, Simon Christopher
  • Milner, Phillip J.
  • Siegelman, Rebecca L.

Abstract

Achieving the selective and reversible adsorption of CO2 from humid, low partial pressures streams such as the flue gas resulting from the combustion of natural gas in combined cycle power plants (4% CO2) is challenging due to the need for high thermal, oxidative, and hydrolytic stability as well as moderate regeneration conditions to reduce the energy of adsorption/desorption cycling. Appending cyclic primary, secondary diamines, exemplified by 2-(aminomethyl)piperidine (2-ampd), to the metalorganic frameworks Mg2(dobpdc) (dobpdc4 = 4,4-dioxidobiphenyl-3,3-dicarboxylate), Mg2(dotpdc) (dotpdc4 = 4,4''-dioxido-[1,1':4',1''-terphenyl]-3,3''-dicarboxylate) or Mg2(pc-dobpdc) (pc-dobpdc4 = dioxidobiphenyl-4,4'-dicarboxylate) produces adsorbents of the classes EMM-44, EMM-45, and EMM-46, respectively, that display step-shaped adsorption of CO2 at the partial pressures required for 90% capture from natural gas flue gas at temperatures up to or exceeding 60 °C. Using a cyclic diamine in place of a diamine functionalized with bulky alkyl groups enables fast adsorption/desorption kinetics with sharp CO2 adsorption and desorption steps.

IPC Classes  ?

  • B01J 20/22 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
  • B01D 53/04 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents

97.

OVERCOMING TWO CARBON DIOXIDE ADSORPTION STEPS IN DIAMINE-APPENDED METAL-ORGANIC FRAMEWORKS

      
Document Number 03071263
Status Pending
Filing Date 2018-07-25
Open to Public Date 2019-02-07
Owner
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
  • EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (Canada)
Inventor
  • Long, Jeffrey R.
  • Weston, Simon Christopher
  • Milner, Phillip J.
  • Martell, Jeffrey D.
  • Siegelman, Rebecca L.

Abstract

Primary, secondary (10,20) alkylethylenediamine- and alkylpropylenediamine- appended variants of metal-organic framework are provided for CO2 capture applications. Increasing the size of the alkyl group on the secondary amine enhances the stability to diamine volatilization from the metal sites. Two-step adsorption/desorption profiles are overcome by minimizing steric interactions between adjacent ammonium carbamate chains. For instance, the isoreticularly expanded framework Mg2(dotpdc) (dotpdc4- =4,4"dioxido - [1, 1':4',1"-terphenyl]-3,3"-dicarboxylate), yields diamine-appended adsorbents displaying a single CO2 adsorption step. Further, use of the isomeric framework Mg-IRMOF-74-II or Mg2(pc-dobpdc) (pc-dobpdc4- = 3,3-dioxidobiphenyl-4,4-dicarboxylate, pc = para-carboxylate) also leads to a single CO2 adsorption step with bulky diamines. By relieving steric interactions between adjacent ammonium carbamate chains, these frameworks enable step-shaped CO2 adsorption, decreased water co-adsorption, and increased stability to diamine loss. Variants of Mg2(dotpdc) and Mg2(pc-dobpdc) functionalized with large diamines such as N-(n-heptyl)ethylenediami ne have utility as adsorbents for carbon capture applications.

IPC Classes  ?

  • B01J 20/28 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
  • B01J 20/22 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material

98.

S-ENANTIOMERS OF BETA-HYDROXYBUTYRATE AND BUTANEDIOL AND METHODS FOR USING SAME

      
Document Number 03070453
Status Pending
Filing Date 2018-07-19
Open to Public Date 2019-01-24
Owner
  • BUCK INSTITUTE FOR RESEARCH ON AGING (Canada)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
  • THE J. DAVID GLADSTONE INSTITUTES (Canada)
Inventor
  • Verdin, Eric
  • Newman, John C.

Abstract

In various embodiments a compound comprising the enantiomerically enriched S-isomer S-BHB-S-1,3-butanediol is provided along with methods of use thereof.

IPC Classes  ?

  • C07C 69/675 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
  • A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
  • A61P 25/08 - Antiepileptics; Anticonvulsants
  • A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

99.

TRAJECTORY ARRAY GUIDE SYSTEM

      
Document Number 03070087
Status Pending
Filing Date 2018-07-17
Open to Public Date 2019-01-24
Owner
  • VOYAGER THERAPEUTICS, INC. (Canada)
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Kells, Adrian Philip
  • Schreck, Stefan
  • Luttich, Edward H.
  • Bloch, Kenneth A.
  • Bankiewicz, Krystof

Abstract

The present disclosure presents a trajectory array guide system (19) for defining a trajectory to a target location in the brain of a subject and for guiding an elongated tool along the trajectory. The trajectory array guide system (19) can comprise a base (450), an array guide (320), an imaging unit (360), and an elongated handle (440) configured for connection with a stereotaxic navigation system. The present disclosure presents a method of using a trajectory array guide system (19) for defining a trajectory to a target location in the brain of a subject and for guiding an elongated tool along the trajectory.

IPC Classes  ?

  • A61B 17/34 - Trocars; Puncturing needles
  • A61B 90/10 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis
  • A61B 90/11 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges for stereotaxic surgery, e.g. frame-based stereotaxis with guides for needles or instruments, e.g. arcuate slides or ball joints
  • A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
  • A61B 34/20 - Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
  • A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging

100.

SIMPLE ROUTE TO HIGHLY CONDUCTIVE POROUS GRAPHENE FROM CARBON NANODOTS FOR SUPERCAPACITOR APPLICATIONS

      
Document Number 03067725
Status Pending
Filing Date 2018-07-12
Open to Public Date 2019-01-17
Owner THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Canada)
Inventor
  • Strauss, Volker
  • Kaner, Richard B.
  • El-Kady, Maher F.

Abstract

Disclosed herein are methods and compositions directed to a promising class of nanomaterials called organic nanoparticles, or carbon nanodots. The present disclosure provides a facile method for the conversion of biomolecule-based carbon nanodots into high surface area three-dimensional graphene networks with excellent electrochemical properties.

IPC Classes  ?

  • H01M 4/88 - Processes of manufacture
  • H01M 8/22 - Fuel cells in which the fuel is based on materials comprising carbon or oxygen or hydrogen and other elements; Fuel cells in which the fuel is based on materials comprising only elements other than carbon, oxygen or hydrogen
  1     2     3     ...     13        Next Page